Genetically modified T cells in cancer therapy: Opportunities and challenges

DMM Disease Models and Mechanisms

Volumn 8, Issue 4, 2015, Pages 337-350

  Sharpe, Michaela ^a   Mount, Natalie ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

CAR; Clinical trial; Efficacy; Gene modification; Immunotherapies; Manufacturing; Oncology; Regulation; Safety; T cell; TCR

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIBODY SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; DNA MODIFICATION; DOWN REGULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; GENETIC PROCEDURES; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; GENETIC TECHNIQUES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84927513482     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.018036     Document Type: Review

References (127)

1. Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A. D., Pouw, N., Debets, R., Kieback, E. et al. (2010). Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565-570, 1p, 570.
2. Berger, C., and Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C. and Riddell, S. R. (2008). Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest. 118, 294-305.
3. Besser, M. J., Shapira-Frommer, R., Itzhaki, O., and Treves, A. J., Zippel, D. B., Levy, D., Kubi, A., Shoshani, N., Zikich, D., Ohayon, Y. et al. (2013). Adoptive transfer of tumour infiltrating lymphocytes in metastatic melanoma patients: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 19, 4792-4800.
4. Blankenstein, T., and Coulie, P. G., Gilboa, E. and Jaffee, E. M. (2012). The determinants of tumour immunogenicity. Nat. Rev. Cancer 12, 307-313.
5. Brentjens, R., Yeh, R., Bernal, Y., Riviere, I. and Sadelain, M. (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666-668.
6. Bridgeman, J. S., and Hawkins, R. E., Bagley, S., Blaylock, M., Holland, M. and Gilham, D. E. (2010). The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 184, 6938-6949.
7. Buckland, K. F. and Gaspar, H. B. (2014). Gene and cell therapy for children - new medicines, new challenges? Adv. Drug Deliv. Rev. 73, 162-169.
8. Bunse, M., and Bendle, G. M., Linnemann, C., Bies, L., Schulz, S., Schumacher, T. N. and Uckert, W. (2014). RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol. Ther. 22, 1983-1991.
9. Cameron, B. J., and Gerry, A. B., Dukes, J., Harper, J. V., Kannan, V., and Bianchi, F. C., Grand, F., Brewer, J. E., Gupta, M., Plesa, G. et al. (2013). Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103.
10. Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F. and Alesse, E. (2012). Targeting costimulatory molecules to improve antitumor immunity. J. Biomed. Biotechnol. 2012, 926321.
11. Carpenito, C., and Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., and Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M. et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360-3365.
12. Casati, A., Varghaei-Nahvi, A., Feldman, S. A., Assenmacher, M., and Rosenberg, S. A., Dudley, M. E. and Scheffold, A. (2013). Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol. Immunother. 62, 1563-1573.
13. Casucci, M., and Hawkins, R. E., Dotti, G. and Bondanza, A. (2015). Overcoming the toxicity hurdles of genetically targeted T cells. Cancer Immunol. Immunother. 64, 123-130.
14. Cheng, M., Chen, Y., Xiao, W., Sun, R. and Tian, Z. (2013). NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 10, 230-252.
15. Cobbold, M., De La Peña, H., Norris, A., Polefrone, J. M., Qian, J., English, A. M., Cummings, K. L., Penny, S., Turner, J. E., Cottine, J. et al. (2013). MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia. Sci. Transl. Med. 5, 203ra125.
16. Cohen, C. J., Zhao, Y., Zheng, Z., Rosenberg, S. A. and Morgan, R. A. (2006). Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 66, 8878-8886.
17. Cohen, C. J., and Li, Y. F., El-Gamil, M., Robbins, P. F., Rosenberg, S. A. and Morgan, R. A. (2007). Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898-3903.
18. Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M. et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25.
19. de Witte, M. A., Coccoris, M., Wolkers, M. C., van den Boom, M. D., Mesman, E. M., Song, J. Y., van der Valk, M., Haanen, J. B. and Schumacher, T. N. (2006). Targeting self-antigens through allogeneic TCR gene transfer. Blood 108, 870-877.
20. Dodo, K., Chono, H., Saito, N., Tanaka, Y., Tahara, K., Nukaya, I. and Mineno, J. (2014). An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking. PLoS ONE 9, e86275.
21. Driessens, G., Kline, J. and Gajewski, T. F. (2009). Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol. Rev. 229, 126-144.
22. Dudley, M. E., and Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F. et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233-5239.
23. Dudley, M. E., and Gross, C. A., Somerville, R. P. T., Hong, Y., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M. et al. (2013). Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31, 2152-2159.
24. Duong, C. P., and Westwood, J. A., Berry, L. J., Darcy, P. K. and Kershaw, M. H. (2011). Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 3, 33-48.
25. Eichler, H. G., Oye, K., Baird, L. G., Abadie, E., Brown, J., Drum, C. L., Ferguson, J., Garner, S., Honig, P., Hukkelhoven, M. et al. (2012). Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91, 426-437.
26. Eshhar, Z., Waks, T., Gross, G. and Schindler, D. G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720-724.
27. Finney, H. M., and Lawson, A. D., Bebbington, C. R. and Weir, A. N. (1998). Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791-2797.
28. Flemming, A. (2014). Deal watch: Pfizer and GSK join race for T cell cancer therapies. Nat. Rev. Drug Discov. 13, 568-569.
29. Fuster, M. M. and Esko, J. D. (2005). The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 5, 526-542.
30. Gao, L., Bellantuono, I., Elsässer, A., Marley, S. B., and Gordon, M. Y., Goldman, J. M. and Stauss, H. J. (2000). Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95, 2198-2203.
31. Gattinoni, L., and Klebanoff, C. A., Palmer, D. C., Wrzesinski, C., Kerstan, N. K., Yu, Z., and Finkelstein, S. E., Theoret, M. R., Rosenberg, S. A. and Restifo, N. P. (2005a). Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumour efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616-1626.
32. Gattinoni, L., and Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., and Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M. et al. (2005b). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202, 907-912.
33. Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., and Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C. et al. (2011). A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290-1297.
34. + B-cell leukaemias. Blood 124, 21.
35. Govers, C., Sebestyén, Z., Coccoris, M., Willemsen, R. A. and Debets, R. (2010). T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol. Med. 16, 77-87.
36. Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., and Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F. et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
37. Haga-Friedman, A., Horovitz-Fried, M. and Cohen, C. J. (2012). Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity. J. Immunol. 188, 5538-5546.
38. Hanahan, D. and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
39. Hara, A., Sato, D. and Sahara, Y. (2014). New governmental regulatory system for stem cell-based therapies in Japan. Therapeutic Innovation & Regulatory Science 2014, 2168479014526877.
40. Hawiger, D., Inaba, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., Ravetch, J. V., Steinman, R. M. and Nussenzweig, M. C. (2001). Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-780.
41. Hegde, M., Corder, A., Chow, K. K., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y. J., Baskin, D. S., Merchant, F. A., Brawley, V. S. et al. (2013). Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol. Ther. 21, 2087-2101.
42. Heslop, H. E. (2010). Safer CARS. Mol. Ther. 18, 661-662.
43. Heslop, H. E., and Slobod, K. S., Pule, M. A., Hale, G. A., Rousseau, A., and Smith, C. A., Bollard, C. M., Liu, H., Wu, M. F., Rochester, R. J. et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925-935.
44. + T cells mediate superior antitumor immunity. Proc. Natl. Acad. Sci. USA 106, 17469-17474.
45. Hinrichs, C. S., and Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., and Klebanoff, C. A., Johnson, L. A., Kerkar, S. P., Yang, S. et al. (2011). Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 117, 808-814.
46. John, L. B., Devaud, C., Duong, C. P., and Yong, C. S., Beavis, P. A., Haynes, N. M., Chow, M. T., Smyth, M. J., Kershaw, M. H. and Darcy, P. K. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636-5646.
47. Johnson, L. A., and Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., and Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R. et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546.
48. Jones, S., Zhang, X., Parsons, D. W., and Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A. et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
49. Joshi, N. S. and Kaech, S. M. (2008). Effector CD8 T cell development: a balancing act between memory cell potential and terminal differentiation. J. Immunol. 180, 1309-1315.
50. Kalos, M., and Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A. and June, C. H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73.
51. Kaneko, S., Mastaglio, S., Bondanza, A., Ponzoni, M., Sanvito, F., Aldrighetti, L., Radrizzani, M., La Seta-Catamancio, S., Provasi, E., Mondino, A. et al. (2009). IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113, 1006-1015.
52. Kawakami, Y., Eliyahu, S., Delgado, C. H., and Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T. and Rosenberg, S. A. (1994). Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91, 3515-3519.
53. Kershaw, M. H., and Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., and Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L. et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106-6115.
54. Kershaw, M. H., Westwood, J. A. and Darcy, P. K. (2013). Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525-541.
55. Klebanoff, C. A., and Khong, H. T., Antony, P. A., Palmer, D. C. and Restifo, N. P. (2005a). Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26, 111-117.
56. Klebanoff, C. A., Gattinoni, L., Torabi-Parizi, P., Kerstann, K., and Cardones, A. R., Finkelstein, S. E., Palmer, D. C., Antony, P. A., Hwang, S. T., Rosenberg, S. A. et al. (2005b). Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl. Acad. Sci. USA 102, 9571-9576.
57. Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P., Ji, Y., Hinrichs, C. S., Borman, Z. A., Kerkar, S. P., Scott, C. D., Finkelstein, S. E. et al. (2011). Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 17, 5343-5352.
58. Klebanoff, C. A., Gattinoni, L. and Restifo, N. P. (2012). Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J. Immunother. 35, 651-660.
59. Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. and Sadelain, M. (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71-75.
60. Krause, A., and Guo, H. F., Latouche, J. B., Tan, C., Cheung, N. K. and Sadelain, M. (1998). Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619-626.
61. Kuball, J., and Dossett, M. L., Wolfl, M., Ho, W. Y., and Voss, R. H., Fowler, C. and Greenberg, P. D. (2007). Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109, 2331-2338.
62. Kunert, A., Straetemans, T., Govers, C., Lamers, C., Mathijssen, R., Sleijfer, S. and Debets, R. (2013). TCR-engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness and sensitization of tumor milieu. Front. Immunol. 4, 363.
63. Kvistborg, P., and Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N., Linnemann, C., van Buuren, M. M., Urbanus, J. H. et al. (2012). TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 1, 409-418.
64. Lagisetty, K. H. and Morgan, R. A. (2012). Cancer therapy with genetically-modified T cells for the treatment of melanoma. J. Gene Med. 14, 400-404.
65. Lamers, C. H., Sleijfer, S., Vulto, A. G., and Kruit, W. H., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G. and Oosterwijk, E. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22.
66. Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H. and Powell, D. J., Jr (2013). Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res 1, 43-53.
67. Lee, D. W., and Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., and Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N. et al. (2014). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517-528.
68. Linette, G. P., and Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., and Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J. et al. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863-871.
69. Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E. et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050-6056.
70. Lu, Y. C., Yao, X., Li, Y. F., El-Gamil, M., Dudley, M. E., Yang, J. C., Almeida, J. R., Douek, D. C., Samuels, Y., Rosenberg, S. A. et al. (2013). Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol. 190, 6034-6042.
71. Lu, Y. C., Yao, X., Crystal, J. S., and Li, Y. F., El-Gamil, M., Gross, C., Davis, L., Dudley, M. E., Yang, J. C., Samuels, Y. et al. (2014). Efficient identification of mutated cancer antigens recognised by T cells associated with durable tumor regressions. Clin. Cancer Res. 20, 3401-3410.
72. Maher, J. (2012). Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol. 2012, 278093.
73. Maher, J. (2014). Clinical immunotherapy of B-cell malignancy using CD19-targeted CAR T-cells. Curr. Gene Ther. 14, 35-43.
74. Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., and Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F. et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517.
75. Maus, M. V., and Grupp, S. A., Porter, D. L. and June, C. H. (2014a). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625-2635.
76. Maus, M. V., and Haas, A. R., Beatty, G. L., Albelda, S. M., and Levine, B. L., Liu, X., Zhao, Y., Kalos, M. and June, C. H. (2014b). T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26-31.
77. Miller, J. S. (2013). Therapeutic applications: natural killer cells in the clinic. Hematology Am. Soc. Hematol. Educ. Program 2013, 247-253.
78. Moeller, M., and Haynes, N. M., Kershaw, M. H., Jackson, J. T., and Teng, M. W., Street, S. E., Cerutti, L., Jane, S. M., Trapani, J. A., Smyth, M. J. et al. (2005). Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. Blood 106, 2995-3003.
79. Moeller, M., and Kershaw, M. H., Cameron, R., Westwood, J. A., and Trapani, J. A., Smyth, M. J. and Darcy, P. K. (2007). Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res. 67, 11428-11437.
80. Montes, M., Rufer, N., Appay, V., Reynard, S., and Pittet, M. J., Speiser, D. E., Guillaume, P., Cerottini, J. C., Romero, P. and Leyvraz, S. (2005). Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin. Exp. Immunol. 142, 292-302.
81. Morgan, R. A., and Dudley, M. E., Wunderlich, J. R., Hughes, M. S., and Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P. et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
82. Morgan, R. A., and Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M. and Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851.
83. Morgan, R. A., Chinnasamy, N., Abate-Daga, D., Gros, A., and Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M. et al. (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36, 133-151.
84. Morrison, C. (2014). Developers seek to finetune toxicity of T-cell therapies. Nat. Biotechnol. 32, 1171-1172.
85. Muniappan, A., Banapour, B., Lebkowski, J. and Talib, S. (2000). Ligand-mediated cytolysis of tumor cells: use of heregulin-ζ chimeras to redirect cytotoxic T lymphocytes. Cancer Gene Ther. 7, 128-134.
86. Norde, W. J., Hobo, W., van der Voort, R. and Dolstra, H. (2012). Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. Blood 120, 728-736.
87. Ormandy, L. A., Hillemann, T., Wedemeyer, H., Manns, M. P., Greten, T. F. and Korangy, F. (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res. 65, 2457-2464.
88. Palucka, K., Ueno, H., Roberts, L., Fay, J. and Banchereau, J. (2011). Dendritic cell subsets as vectors and targets for improved cancer therapy. Curr. Top. Microbiol. Immunol. 344, 173-192.
89. Park, J. R., and Digiusto, D. L., Slovak, M., Wright, C., Naranjo, A., Wagner, J., Meechoovet, H. B., Bautista, C., Chang, W. C., Ostberg, J. R. et al. (2007). Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825-833.
90. Parkhurst, M. R., and Yang, J. C., Langan, R. C., Dudley, M. E., and Nathan, D. A., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M. et al. (2011). T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19, 620-626.
91. Paulos, C. M., Wrzesinski, C., Kaiser, A., Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z. et al. (2007). Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J. Clin. Invest. 117, 2197-2204.
92. Pegram, H. J., and Lee, J. C., Hayman, E. G., Imperato, G. H., and Tedder, T. F., Sadelain, M. and Brentjens, R. J. (2012). Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133-4141.
93. Pegram, H. J., Park, J. H. and Brentjens, R. J. (2014). CD28z CARs and armored CARs. Cancer J. 20, 127-133.
94. Pinzon-Charry, A., Maxwell, T. and López, J. A. (2005). Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol. Cell Biol. 83, 451-461.
95. Porter, D. L., and Levine, B. L., Kalos, M., Bagg, A. and June, C. H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
96. Pouw, N., Treffers-Westerlaken, E., Kraan, J., Wittink, F., ten Hagen, T., Verweij, J. and Debets, R. (2010). Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 59, 921-931.
97. Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., and Liu, P. Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J. et al. (2012). Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807-815.
98. Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., and Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z. et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270.
99. Robbins, P. F., and Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J., Powell, D. J., Jr and Rosenberg, S. A. (2004). Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173, 7125-7130.
100. Robbins, P. F., and Li, Y. F., El-Gamil, M., Zhao, Y., and Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A. et al. (2008). Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116-6131.
101. Robbins, P. F., and Morgan, R. A., Feldman, S. A., Yang, J. C., and Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L. et al. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924.
102. Robbins, P. F., and Lu, Y. C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E. et al. (2013). Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752.
103. Rooney, C. and Leen, A. (2012). Moving successful virus-specific T-cell therapy for hematopoietic stem cell recipients to late phase clinical trials. Mol. Ther. Nucleic Acids. 1, e55.
104. Rosenberg, S. A., and Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., and Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A. et al. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319, 1676-1680.
105. Rosenberg, S. A., and Yang, J. C., Sherry, R. M., Kammula, U. S., and Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R. et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550-4557.
106. Ruella, M. and Kalos, M. (2014). Adoptive immunotherapy for cancer. Immunol. Rev. 257, 14-38.
107. Schaft, N., Lankiewicz, B., Drexhage, J., Berrevoets, C., and Moss, D. J., Levitsky, V., Bonneville, M., Lee, S. P., McMichael, A. J., Gratama, J. W. et al. (2006). T cell retargeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. Int. Immunol. 18, 591-601.
108. Schmid, D. A., and Irving, M. B., Posevitz, V., Hebeisen, M., Posevitz-Fejfar, A., Sarria, J. C., Gomez-Eerland, R., Thome, M., Schumacher, T. N., Romero, P. et al. (2010). Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184, 4936-4946.
109. Schmitt, T. M., Ragnarsson, G. B. and Greenberg, P. D. (2009). T cell receptor gene therapy for cancer. Hum. Gene Ther. 20, 1240-1248.
110. Sherman, R. E., Li, J., Shapley, S., Robb, M. and Woodcock, J. (2013). Expediting drug development - the FDA's new "breakthrough therapy" designation. N. Engl. J. Med. 369, 1877-1880.
111. Singh, H., and Figliola, M. J., Dawson, M. J., Huls, H., Olivares, S., Switzer, K., Mi, T., Maiti, S., Kebriaei, P., Lee, D. A. et al. (2011). Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 71, 3516-3527.
112. Sommermeyer, D. and Uckert, W. (2010). Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J. Immunol. 184, 6223-6231.
113. Stanislawski, T., and Voss, R. H., Lotz, C., Sadovnikova, E., Willemsen, R. A., Kuball, J., Ruppert, T., Bolhuis, R. L., Melief, C. J., Huber, C. et al. (2001). Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2, 962-970.
114. Teachey, D. T., and Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., and Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A. et al. (2013). Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 121, 5154-5157.
115. Thomas, S., and Xue, S. A., Cesco-Gaspere, M., San José, E., Hart, D. P., Wong, V., Debets, R., Alarcon, B., Morris, E. and Stauss, H. J. (2007). Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells. J. Immunol. 179, 5803-5810.
116. Till, B. G., and Jensen, M. C., Wang, J., Chen, E. Y., and Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J. et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271.
117. Tran, K. Q., Zhou, J., Durflinger, K. H., and Langhan, M. M., Shelton, T. E., Wunderlich, J. R., Robbins, P. F., Rosenberg, S. A. and Dudley, M. E. (2008). Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J. Immunother. 31, 742-751.
118. Uttenthal, B. J., Chua, I., Morris, E. C. and Stauss, H. J. (2012). Challenges in T cell receptor gene therapy. J. Gene Med. 14, 386-399.
119. Vacchelli, E., Vitale, I., Eggermont, A., Fridman, W. H., Fucikova, J., Cremer, I., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G. et al. (2013). Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2, e25771.
120. van Loenen, M. M., de Boer, R., Amir, A. L., Hagedoorn, R. S., Volbeda, G. L., Willemze, R., van Rood, J. J., Falkenburg, J. H. and Heemskerk, M. H. (2010). Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc. Natl. Acad. Sci. USA 107, 10972-10977.
121. Voss, R. H., and Willemsen, R. A., Kuball, J., Grabowski, M., Engel, R., and Intan, R. S., Guillaume, P., Romero, P., Huber, C. and Theobald, M. (2008). Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J. Immunol. 180, 391-401.
122. Walter, E. A., and Greenberg, P. D., Gilbert, M. J., Finch, R. J., and Watanabe, K. S., Thomas, E. D. and Riddell, S. R. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044.
123. Weber, J., Atkins, M., Hwu, P., Radvanyi, L., Sznol, M., Yee, C.; Immunotherapy Task Force of the NCI Investigational Drug Steering Committee (2011). White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on Adoptive Cell Therapy. Clin. Cancer Res. 17, 1664-1673.
124. Xing, Y. and Hogquist, K. A. (2012). T-cell tolerance: central and peripheral. Cold Spring Harb. Perspect. Biol. 4, a006957.
125. Zhang, T., Wu, M. R. and Sentman, C. L. (2012). An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J. Immunol. 189, 2290-2299.
126. Zhou, G. and Levitsky, H. I. (2007). Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178, 2155-2162.
127. Zou, W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5, 263-274.